|
1
|
Skelton TP, Zeng C, Nocks A and
Stamenkovic I: Glycosylation provides both stimulatory and
inhibitory effects on cell surface and soluble CD44 binding to
hyaluronan. J Cell Biol. 140:431–446. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Diamond MS, Staunton DE, Marlin SD and
Springer TA: Binding of the integrin Mac-1 (CD11b/CD18) to the
third immunoglobulin-like domain of ICAM-1 (CD54) and its
regulation by glycosylation. Cell. 65:961–971. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
McEvoy LM, Sun H, Frelinger JG and Butcher
EC: Anti-CD43 inhibition of T cell homing. J Exp Med.
185:1493–1498. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dennis JW, Granovsky M and Warren CE:
Glycoprotein glycosylation and cancer progression. Biochim Biophys
Acta. 1473:21–34. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rudd PM, Elliott T, Cresswell P, Wilson IA
and Dwek RA: Glycosylation and the immune system. Science.
291:2370–2376. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hakomori S: Aberrant glycosylation in
cancer cell membranes as focused on glycolipids: Overview and
perspectives. Cancer Res. 45:2405–2414. 1985.PubMed/NCBI
|
|
7
|
Hakomori S: Tumor malignancy defined by
aberrant glycosylation and sphingo (glyco)lipid metabolism. Cancer
Res. 56:5309–5318. 1996.PubMed/NCBI
|
|
8
|
Springer GF: T and Tn, general carcinoma
autoantigens. Science. 224:1198–1206. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Feizi T: Demonstration by monoclonal
antibodies that carbohydrate structures of glycoproteins and
glycolipids are onco-developmental antigens. Nature. 314:53–57.
1985. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Julien S, Adriaenssens E, Ottenberg K,
Furlan A, Courtand G, Vercoutter-Edouart AS, Hanisch FG, Delannoy P
and Le Bourhis X: ST6GalNAc I expression in MDA-MB-231 breast
cancer cells greatly modifies their O-glycosylation pattern and
enhances their tumourigenicity. Glycobiology. 16:54–64. 2006.
View Article : Google Scholar
|
|
11
|
Taylor-Papadimitriou J, Burchell J, Miles
DW and Dalziel M: MUC1 and cancer. Biochim Biophys Acta.
1455:301–313. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hakomori S: Carbohydrate-to-carbohydrate
interaction in basic cell biology: A brief overview. Arch Biochem
Biophys. 426:173–181. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sørensen AL, Reis CA, Tarp MA, Mandel U,
Ramachandran K, Sankaranarayanan V, Schwientek T, Graham R,
Taylor-Papadimitriou J, Hollingsworth MA, et al: Chemoenzymatically
synthesized multimeric Tn/STn MUC1 glycopeptides elicit
cancer-specific anti-MUC1 antibody responses and override
tolerance. Glycobiology. 16:96–107. 2006. View Article : Google Scholar
|
|
14
|
Tarp MA, Sørensen AL, Mandel U, Paulsen H,
Burchell J, Taylor-Papadimitriou J and Clausen H: Identification of
a novel cancer-specific immunodominant glycopeptide epitope in the
MUC1 tandem repeat. Glycobiology. 17:197–209. 2007. View Article : Google Scholar
|
|
15
|
Madsen CB, Petersen C, Lavrsen K, Harndahl
M, Buus S, Clausen H, Pedersen AE and Wandall HH: Cancer associated
aberrant protein O-glycosylation can modify antigen processing and
immune response. PLoS One. 7:e501392012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Apostolopoulos V, Pietersz GA, Xing PX,
Lees CJ, Michael M, Bishop J and McKenzie IF: The immunogenicity of
MUC1 peptides and fusion protein. Cancer Lett. 90:21–26. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wandall HH, Blixt O, Tarp MA, Pedersen JW,
Bennett EP, Mandel U, Ragupathi G, Livingston PO, Hollingsworth MA,
Taylor-Papadimitriou J, et al: Cancer biomarkers defined by
autoantibody signatures to aberrant O-glycopeptide epitopes. Cancer
Res. 70:1306–1313. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xu Y, Gendler SJ and Franco A: Designer
glycopeptides for cytotoxic T cell-based elimination of carcinomas.
J Exp Med. 199:707–716. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Blixt O, Bueti D, Burford B, Allen D,
Julien S, Hollingsworth M, Gammerman A, Fentiman I,
Taylor-Papadimitriou J and Burchell JM: Autoantibodies to
aberrantly glycosylated MUC1 in early stage breast cancer are
associated with a better prognosis. Breast Cancer Res. 13:R252011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dabelsteen E: Cell surface carbohydrates
as prognostic markers in human carcinomas. J Pathol. 179:358–369.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hollingsworth MA and Swanson BJ: Mucins in
cancer: Protection and control of the cell surface. Nat Rev Cancer.
4:45–60. 2004. View
Article : Google Scholar
|
|
22
|
Kim YJ and Varki A: Perspectives on the
significance of altered glycosylation of glycoproteins in cancer.
Glycoconj J. 14:569–576. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Miles DW, Happerfield LC, Smith P,
Gillibrand R, Bobrow LG, Gregory WM and Rubens RD: Expression of
sialyl-Tn predicts the effect of adjuvant chemotherapy in
node-positive breast cancer. Br J Cancer. 70:1272–1275. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Joziasse DH: Mammalian
glycosyltransferases: Genomic organization and protein structure.
Glycobiology. 2:271–277. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Le Marer N, Laudet V, Svensson EC,
Cazlaris H, Van Hille B, Lagrou C, Stehelin D, Montreuil J, Verbert
A and Delannoy P: The c-Ha-ras oncogene induces increased
expression of beta-galactoside alpha-2, 6-sialyltransferase in rat
fibroblast (FR3T3) cells. Glycobiology. 2:49–56. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bennett EP, Hassan H, Mandel U,
Hollingsworth MA, Akisawa N, Ikematsu Y, Merkx G, van Kessel AG,
Olofsson S and Clausen H: Cloning and characterization of a close
homologue of human UDP-N-acetyl-alpha-D-galactosamine: Polypeptide
N-acetylgalactosaminyltransferase-T3, designated GalNAc-T6.
Evidence for genetic but not functional redundancy. J Biol Chem.
274:25362–25370. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Brooks SA, Carter TM, Bennett EP, Clausen
H and Mandel U: Immunolocalisation of members of the polypeptide
N-acetylgalactosaminyl transferase (ppGalNAc-T) family is
consistent with biologically relevant altered cell surface
glycosylation in breast cancer. Acta Histochem. 109:273–284. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Freire T, Berois N, Sóñora C, Varangot M,
Barrios E and Osinaga E: UDP-N-acetyl-D-galactosamine: Polypeptide
N-acetylgalactosaminyltransferase 6 (ppGalNAc-T6) mRNA as a
potential new marker for detection of bone marrow-disseminated
breast cancer cells. Int J Cancer. 119:1383–1388. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nomoto M, Izumi H, Ise T, Kato K, Takano
H, Nagatani G, Shibao K, Ohta R, Imamura T, Kuwano M, et al:
Structural basis for the regulation of
UDP-N-acetyl-alpha-D-galactosamine: Polypeptide
N-acetylgalactosaminyl transferase-3 gene expression in
adenocarcinoma cells. Cancer Res. 59:6214–6222. 1999.
|
|
30
|
Paulson JC and Colley KJ:
Glycosyltransferases. Structure, localization, and control of cell
type-specific glycosylation. J Biol Chem. 264:17615–17618.
1989.PubMed/NCBI
|
|
31
|
Hebbar M, Krzewinski-Recchi MA, Hornez L,
Verdière A, Harduin-Lepers A, Bonneterre J, Delannoy P and Peyrat
JP: Prognostic value of tumoral sialyltransferase expression and
circulating E-selectin concentrations in node-negative breast
cancer patients. Int J Biol Markers. 18:116–122. 2003.PubMed/NCBI
|
|
32
|
Recchi MA, Hebbar M, Hornez L,
Harduin-Lepers A, Peyrat JP and Delannoy P: Multiplex reverse
transcription polymerase chain reaction assessment of
sialyltransferase expression in human breast cancer. Cancer Res.
58:4066–4070. 1998.PubMed/NCBI
|
|
33
|
Park JH, Nishidate T, Kijima K, Ohashi T,
Takegawa K, Fujikane T, Hirata K, Nakamura Y and Katagiri T:
Critical roles of mucin 1 glycosylation by transactivated
polypeptide N-acetylgalactosaminyltransferase 6 in mammary
carcinogenesis. Cancer Res. 70:2759–2769. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Berois N, Mazal D, Ubillos L, Trajtenberg
F, Nicolas A, Sastre-Garau X, Magdelenat H and Osinaga E:
UDP-N-acetyl-D-galactosamine: Polypeptide
N-acetylgalactosaminyltransferase-6 as a new immunohistochemical
breast cancer marker. J Histochem Cytochem. 54:317–328. 2006.
View Article : Google Scholar
|
|
35
|
Casey RC, Oegema TR Jr, Skubitz KM,
Pambuccian SE, Grindle SM and Skubitz AP: Cell membrane
glycosylation mediates the adhesion, migration, and invasion of
ovarian carcinoma cells. Clin Exp Metastasis. 20:143–152. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang L and Ten Hagen KG: The cellular
microenvironment and cell adhesion: A role for O-glycosylation.
Biochem Soc Trans. 39:378–382. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Remmele W and Stegner HE: Recommendation
for uniform definition of an immunoreactive score (IRS) for
immunohistochemical estrogen receptor detection (ER-ICA) in breast
cancer tissue. Pathologe. 8:138–140. 1987.In German. PubMed/NCBI
|
|
38
|
Andergassen U, Liesche F, Kölbl AC, Ilmer
M, Hutter S, Friese K and Jeschke U: Glycosyltransferases as
markers for early tumourigenesis. Biomed Res Int.
2015L:7926722015.
|
|
39
|
Park JH, Katagiri T, Chung S, Kijima K and
Nakamura Y: Polypeptide N-acetylgalactosaminyltransferase 6
disrupts mammary acinar morphogenesis through O-glycosylation of
fibronectin. Neoplasia. 13:320–326. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang L, Gallup M, Zlock L, Chen YT,
Finkbeiner WE and McNamara NA: Pivotal role of MUC1 glycosylation
by cigarette smoke in modulating disruption of airway adherens
junctions in vitro. J Pathol. 234:60–73. 2014. View Article : Google Scholar : PubMed/NCBI
|
